P
MRNA icon

&Partners’s Moderna MRNA Stock Holding History

&Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$332K Buy
+6,446
New +$301K ﹤0.01% 1929
2022
Q1 		– Sell
-900
Closed -$229K – 201
2021
Q4 		$229K Hold
900
– – 0.14% 157
2021
Q3 		$346K Hold
900
– – 0.22% 106
2021
Q2 		$211K Buy
+900
New +$161K 0.14% 167

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

&Partners's MRNA Position: Q1 2026 in Review

&Partners opened a new position in Moderna (MRNA) in Q1 2026: 6,446 shares worth $332K. The stake represents ﹤0.01% of the portfolio and ranks #1929 among its holdings. This is a return to the name: &Partners previously reported a position in MRNA as recently as Q4 2021.

&Partners first reported a position in MRNA in Q2 2021 and has held it in 4 quarters since. The position peaked at $346K in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • &Partners held 6,446 shares of Moderna worth $332K as of Q1 2026.
  • Moderna was a new &Partners position in Q1 2026.
  • Moderna made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1929 holding.
  • &Partners first reported a position in Moderna in Q2 2021 and has held it in 4 quarters since.
  • &Partners's Moderna position peaked at $346K in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.